Liberum Capital Reconfirms Its Buy Rating on RELX Plc (LON:REL) Shares Today


RELX Plc (LON:REL) Rating Reaffirmed

This Morning, Friday, 30 November, RELX Plc (LON:REL)‘s Buy rating was reiterated at Liberum Capital in a research report.

RELX PLC (LON:REL) Ratings Coverage

Among 8 analysts covering RELX Plc (LON:REL), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. RELX Plc has GBX 1940 highest and GBX 1550 lowest target. GBX 1711.88’s average target is 4.86% above currents GBX 1632.5 stock price. RELX Plc had 20 analyst reports since June 19, 2018 according to SRatingsIntel. The rating was maintained by UBS on Tuesday, July 24 with “Sell”. The stock has “Buy” rating by Deutsche Bank on Thursday, November 1. The company was maintained on Thursday, July 26 by Liberum Capital. The company was maintained on Wednesday, October 24 by Liberum Capital. UBS maintained the stock with “Sell” rating in Thursday, October 25 report. The firm earned “Outperform” rating on Thursday, November 1 by Credit Suisse. The company was maintained on Friday, October 26 by Barclays Capital. On Friday, October 19 the stock rating was maintained by UBS with “Sell”. The stock of RELX PLC (LON:REL) has “Sell” rating given on Thursday, September 13 by UBS. The firm has “Equal Weight” rating given on Friday, July 6 by Barclays Capital.

The stock decreased 1.36% or GBX 22.5 during the last trading session, reaching GBX 1632.5. About 5.78M shares traded. RELX PLC (LON:REL) has 0.00% since December 2, 2017 and is . It has underperformed by 15.62% the S&P500.

RELX PLC provides information and analytics for professional and business clients in North America, Europe, and internationally. The company has market cap of 32.10 billion GBP. The company's Scientific, Technical & Medical segment offers information, analytics, and tools that help clients make decisions. It has a 19.84 P/E ratio. This segment provides research, reference, and education content; and database and decision tools for scientists, academic institutions, educators, research leaders and administrators, medical researchers, doctors, nurses, and allied health professionals and students, as well as hospitals, research institutions, health insurers, managed healthcare organizations, research-intensive firms, and governments.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.